- Home
- AGIO vs EVT Comparison
AGIO vs EVT Comparison
Compare AGIO & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- EVT
- Stock Information
- Founded
- AGIO 2007
- EVT 2003
- Country
- AGIO United States
- EVT United States
- Employees
- AGIO N/A
- EVT N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- EVT Finance Companies
- Sector
- AGIO Health Care
- EVT Finance
- Exchange
- AGIO Nasdaq
- EVT Nasdaq
- Market Cap
- AGIO 1.4B
- EVT 1.6B
- IPO Year
- AGIO 2013
- EVT N/A
- Fundamental
- Price
- AGIO $27.32
- EVT $22.79
- Analyst Decision
- AGIO Buy
- EVT
- Analyst Count
- AGIO 8
- EVT 0
- Target Price
- AGIO $56.00
- EVT N/A
- AVG Volume (30 Days)
- AGIO 524.5K
- EVT 145.7K
- Earning Date
- AGIO 05-01-2025
- EVT 01-01-0001
- Dividend Yield
- AGIO N/A
- EVT 8.66%
- EPS Growth
- AGIO N/A
- EVT N/A
- EPS
- AGIO 11.45
- EVT 6.63
- Revenue
- AGIO $37,035,000.00
- EVT $69,404,302.00
- Revenue This Year
- AGIO $40.62
- EVT N/A
- Revenue Next Year
- AGIO $216.26
- EVT N/A
- P/E Ratio
- AGIO $2.39
- EVT $3.44
- Revenue Growth
- AGIO 25.96
- EVT N/A
- 52 Week Low
- AGIO $23.42
- EVT $19.20
- 52 Week High
- AGIO $62.58
- EVT $25.83
- Technical
- Relative Strength Index (RSI)
- AGIO 41.34
- EVT 58.14
- Support Level
- AGIO $27.78
- EVT $21.87
- Resistance Level
- AGIO $31.55
- EVT $22.96
- Average True Range (ATR)
- AGIO 1.38
- EVT 0.37
- MACD
- AGIO -0.03
- EVT 0.16
- Stochastic Oscillator
- AGIO 2.98
- EVT 92.13
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.